Dr Reddy's Gilead yearly lenacapavir license
Analysis based on 7 articles · First reported Sep 17, 2026 · Last updated Sep 17, 2026
The deal is a modest positive for Abbott Laboratories, expanding its public-health access portfolio and long-acting HIV pipeline without upfront royalty costs, though revenue impact depends on eventual regulatory approval of once-yearly lenacapavir. For Gilead Sciences it broadens low- and lower-middle-income market access and manufacturing capacity for lenacapavir, a strategic franchise, with limited near-term earnings effect since the annual formulation remains investigational.
Abbott Laboratories announced on September 17, 2026 a royalty-free, non-exclusive voluntary licensing agreement with Gilead Sciences covering investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreement is intended to support manufacturing readiness, technology transfer and future supply planning across 120 high-incidence licensed countries, including India, primarily low- and lower-middle-income nations. It builds on the October 2024 voluntary licence between the two companies covering twice-yearly lenacapavir for HIV prevention and treatment. Once-yearly lenacapavir is still being evaluated in Gilead Sciences' Phase 3 PURPOSE 365 study and has not been approved by any regulatory authority; its safety and efficacy for annual HIV prevention have not been established. The twice-yearly formulation is already approved in multiple countries for treatment of adults with multidrug-resistant HIV and for HIV prevention, and is recommended by the World Health Organization; it has been approved for prevention by the United States — Food and Drug Administration and the European Union — European Medicines Agency. Alongside Abbott Laboratories, Gilead Sciences signed five other voluntary licensing agreements with partners manufacturing twice-yearly lenacapavir, including Emcure Pharmaceuticals, Eva Pharma, Abbott Laboratories, Hetero Drugs and Mylan. In India, Abbott Laboratories and other companies in the broader licensing agreement secured a waiver for local clinical trials, and the subject expert committee reviewing the drug granted a favorable recommendation, with final marketing approval still pending from the India — Central Drugs Standard Control Organisation. Deepak Sapra, CEO of API and Services at Abbott Laboratories, said the deal reflects continued commitment to global HIV prevention efforts and could offer an additional long-acting prevention option where access and adherence remain challenges.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard